The Florida Drug Discovery Acceleration Program is funded by the state of Florida for the 2014-2015 fiscal year through the Department of Health. This program allows for Torrey Pines Institute for Molecular Studies (TPIMS) to share its large collection of compound libraries and expertise to Florida Institutions to accelerate drug discovery and commercialization statewide. Through this program, these compound libraries and services are provided at no cost to our collaborators at universities and non-profit institutes within the state of Florida.
TPIMS COMPOUND LIBRARIES
The TPIMS compound library collection currently consists of over 30 million drug-like compounds and billions of peptides. All of the compound libraries are arranged in the positional scanning format which allows for the testing of millions of compounds using only hundreds of samples. Because of the capability to screen the TPIMS compound libraries with fewer samples, these libraries can be screened in virtually any assay with no adaptation requirements.
PROCESS FOR SCREENING TPIMS COMPOUND LIBRARIES
The process for screening these compound collections consists of the following steps:
- Execute a Material Transfer Agreement (MTA) – This protects the rights of each institute and allows sharing of any intellectual property that is generated.
- Screen the scaffold ranking plate (a single plate containing ~50 samples for screening in an assay) – This is used to prioritize those libraries with the most likelihood for identifying individual, lead compounds for your program.
- Select and screen the full positional scanning library (or libraries) identified from the scaffold ranking plate – This data identifies the individual compounds for synthesis at TPIMS.
- Screen the individual compounds prepared – This will provide lead compounds for the assay under investigation. These compounds can be further developed into potential therapeutics for intervention in human, animal, and/or agricultural diseases.
If you are interested in participating in the Florida Drug Discovery Acceleration Program, please contact:
Greg Welmaker, PhD, MBA